جست‌وجوی استاد و پژوهشگر

Aleksandar Milosavljevicمشاهده پروفایل

استاد

• Genomics
• Cancer Genomics
• Bioinformatics
• +۴ مورد دیگر

Aleksandar Milosavljevic is a Professor and holds the Henry and Emma Meyer Chair in Molecular Genetics at Baylor College of Medicine. He serves as Director of the Program in Quantitative & Computational Biosciences (QCB) and Co-Director of the Computational and Integrative Biomedical Research Center (CIBR). He is also a member of the Dan L Duncan Comprehensive Cancer Center. His research focuses on genomics, epigenomics, and bioinformatics, with a particular emphasis on cancer genomics, extracellular RNA communication, and clinical genome interpretation. Education: PhD from University of California, Santa Cruz (1990). Research interests include developing computational methods for analyzing genomic and epigenomic data, constructing biological atlases (e.g., Human Epigenome Atlas, exRNA Atlas), and advancing clinical genomic applications through projects like ClinGen. His work bridges basic science and translational medicine, with contributions to understanding tumor biology, genetic variant interpretation, and liquid biopsy technologies. Key projects include the NIH Roadmap Epigenomics Initiative, NIH Extracellular RNA Communication Consortium, and ClinGen, which developed tools like the Pathogenicity Calculator and Allele Registry. His lab collaborates widely, addressing challenges in structural genomics, stochastic epigenetic regulation, and precision medicine.

• Stem Cell Research
• Neurosciences
• Regenerative Medicine
• +۴ مورد دیگر

Jonas Frisén is a Professor of Stem Cell Research at Karolinska Institutet, Sweden, leading the Stem Cells in Tissue Homeostasis and Regenerative Medicine group within the Department of Cell and Molecular Biology. His work focuses on stem cell roles in healthy and diseased tissues, including neural, cardiac, and intestinal systems. Key methodologies include 14C dating for cell turnover analysis and spatial transcriptomics. Education: University Medical Degree, Karolinska Institutet (1991) Research Interests: Stem cell dynamics in neural, cardiac, and intestinal tissues Regenerative medicine applications for neurodegenerative and cardiovascular diseases Age-related changes in stem cell function Development of novel genomic and spatial analysis tools Publications: Recent work highlights include studies on latent cardiomyocyte regeneration in heart disease (2025), neurogenic aging trajectories (2025), and spatial immune cell receptor mapping (2023). These studies emphasize translational potential and advanced single-cell technologies. Awards & Funding: Recipient of distinguished professor grants (2023) and Wallenberg Scholar funding (2024). Notable grants include VR awards totaling SEK 660 million for KI researchers in 2023. Labs/Teams: Leads a multidisciplinary group integrating stem cell biology, genomics, and clinical applications. Collaborates with institutions like SciLifeLab and KTH Royal Institute of Technology.

• Bioinformatics
• Computational Genomics
• Transcriptional Regulation
• +۴ مورد دیگر

Zhiping Weng is a Professor and Chair of the Department of Genomics and Computational Biology at the University of Massachusetts Chan Medical School. She holds the Li Weibo Chair in Biomedical Research and is affiliated with the T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. Her research focuses on computational biology, genomics, and systems biology, with a particular emphasis on understanding gene regulation, epigenomics, and small RNA biology. Dr. Weng earned her B.S. in Electrical Engineering from the University of Science and Technology of China (1992) and her Ph.D. in Biomedical Engineering from Boston University (1997). She joined UMass Chan Medical School in 2008 to establish the Program in Bioinformatics and Integrative Biology. Her research integrates computational methods with high-throughput genomics data to study transcriptional regulation, protein interactions, and small RNA mechanisms. Key projects include developing tools for predicting transcription factor binding sites, analyzing nucleosome positioning, and modeling protein complexes. Her lab also explores the role of piRNAs and miRNAs in transposon silencing and developmental processes. Recent work includes studies on tRNA sequencing, koala retrovirus evolution, and the functional annotation of regulatory elements across species. Her contributions span bioinformatics tool development (e.g., ZDOCK for protein docking) and collaborative efforts in genome-wide studies like ENCODE. Dr. Weng advises students and postdocs in computational biology and collaborates extensively on epigenetic and systems biology projects. Her lab is part of the broader genomic research community at UMass Chan, contributing to advancements in personalized medicine and functional genomics.

• Reproductive Biology
• Male Infertility
• Seminal Fluid Signaling
• +۷ مورد دیگر

Dr John Schjenken is a Senior Lecturer at the University of Newcastle's School of Environmental and Life Sciences within the College of Engineering, Science and Environment. He directs the Hunter Medical Research Institute's Infertility and Reproduction Research Program. His research focuses on male contributions to fertility, particularly the role of seminal fluid components and extracellular vesicles in conception and pregnancy outcomes. He has published extensively in journals like Proceedings of the National Academy of Sciences and Communications Biology , with over 1,600 citations and an H-index of 24. Education: PhD in Biological Sciences from the University of Newcastle. Research Interests: Male infertility mechanisms, immune regulation at conception, paternal environmental influences, extracellular vesicle biology, and translational research to improve fertility diagnostics and therapies. Current projects include studying seminal vesicle secretions' impact on fertility and how sperm modulate maternal immunity. Awards: 2021 Rising Star in Reproductive Biology (Society for the Study of Reproduction), multiple early career awards from the Robinson Research Institute and EpiCSA, and recognition for collaborative research on paternal programming. Grants: NHMRC Ideas Grants (2023–2028), HMRI grants, and international collaborations. Total funding exceeds $2.5 million. Teaching: Leads courses in Biotechnology Placement, Molecular Biology, and Reproductive Health Research. Supervised over 18 graduate students across PhD, Honours, and Master's programs. Labs/Teams: Leads the HMRI Infertility and Reproduction Program, collaborates with Dr. David Sharkey at the University of Adelaide, and uses cutting-edge proteomics, transcriptomics, and single-cell analysis techniques.

• Epigenomics
• Genomics
• Inflammation
• +۶ مورد دیگر

Don X. Nguyen is a tenured Associate Professor at the Yale School of Medicine , holding joint appointments in the Department of Pathology and Medical Oncology and Hematology . He co-leads the Cancer Signaling Networks program at the Yale Cancer Center and directs the Nguyen Laboratory , specializing in CNS metastasis biology and epigenetic regulation of tumor progression. PhD in Microbiology & Immunology (University of Rochester, 2004) Postdoctoral Fellowship at Memorial Sloan Kettering Institute (2009) His research focuses on epigenetic regulation in tumor progression, particularly examining cell lineage control , cell-cell communication in disseminated tumor cells, and mechanisms linking drug resistance to brain metastasis . The lab develops novel metastasis models with expertise in central nervous system metastasis biology. Recent publications highlight his work on epigenetic drivers of metastasis (2025), immune landscape profiling in radiation necrosis (2024-2025), and drug resistance mechanisms in EGFR-mutant lung cancer (2024). His team collaborates with clinical researchers like Veronica Chiang and Katerina Politi on translational projects. Scientific honors include: Stewart Trust Scholar (2013) IASLC Young Investigator Award (2012) Yale Center for Clinical Investigation Scholar (2011) Class of 1961 Cancer Research Award (2021) The lab maintains affiliations with the Yale Stem Cell Center , Program in Translational Biomedicine , and SPORE in Lung Cancer initiatives.

Tamas Ordogمشاهده پروفایل

استاد

• Gastrointestinal Neuromuscular Biology
• Interstitial Cells of Cajal
• Enteric Neuroscience
• +۱۲ مورد دیگر

Tamas Ordog, M.D., is a Professor of Physiology at Mayo Clinic in Rochester, Minnesota, with primary appointments in the Department of Physiology & Biomedical Engineering and a joint appointment in the Division of Gastroenterology and Hepatology, Department of Internal Medicine. He leads research in gastrointestinal neuromuscular biology and epigenomics, contributing significantly to understanding motility disorders and gastrointestinal stromal tumors. Primary Appointment: Consultant, Department of Physiology & Biomedical Engineering Joint Appointment: Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine Academic Rank: Professor of Physiology Institution: Mayo Clinic, Rochester, MN Dr. Ordog earned his M.D. from the University of Pecs Medical School, Hungary, followed by postdoctoral training in neuroendocrinology at the University of Texas Medical School at Houston under Dr. Ernst Knobil, and in uterine cell proliferation at the University of Pecs under Dr. Marietta Vertes. His research focuses on the molecular and cellular mechanisms of gastrointestinal motility, particularly interstitial cells of Cajal and enteric neurons. He investigates how epigenetic and metabolic dysregulation contributes to diseases like diabetic gastroparesis and GISTs. Dr. Ordog established the Epigenomics Program at Mayo Clinic’s Center for Individualized Medicine, advancing cutting-edge epigenomic technologies. The most recent publications reflect a strong trend in single-cell and spatial multiomics, AI-assisted imaging, and translational applications in diabetes and cancer. His work integrates genomics, epigenomics, metabolomics, and animal models to identify therapeutic targets. Honoree, Famous Hungarian Neuroscientists in the World, University of Pecs, Hungary, 2017 Recipient, Geza Hetenyi Memorial Medallion and honorary membership, Hungarian Gastroenterological Society, 2010 Recipient, Masters Award in Gastroenterology, PriCara, 2008 Dr. Ordog is actively involved in multiple NIH-funded research projects, including as Principal Investigator (PI) or Co-PI on grants from the National Institute of Diabetes and Digestive and Kidney Diseases. He mentors researchers and leads core facilities such as the Epigenomics and Spatial Biology Core. His lab is part of the Center for Cell Signaling in Gastroenterology and the Enteric Neuroscience Program, fostering interdisciplinary collaboration. His research group utilizes advanced technologies in gene editing, epigenomic profiling, and spatial proteomics, contributing to novel diagnostic and therapeutic strategies for gastrointestinal diseases.

Nicholas Zorkoمشاهده پروفایل

استادیار

• Prostate Cancer
• Immunotherapy
• Natural Killer (NK) Cell Therapy
• +۴ مورد دیگر

Nicholas Zorko, MD, PhD, is an Assistant Professor of Medicine at the University of Minnesota. His work centers on advancing NK cell-based immunotherapies for prostate and other solid tumors, with a focus on B7-H3 and PSMA-targeted tri-specific killer engagers (TriKEs). Research Interests Targeting B7-H3 and PSMA in prostate cancer immunotherapy Enhancing NK cell function in "cold" tumor microenvironments Development of off-the-shelf CAR NK cell therapies Investigating HLA class I expression and immune evasion mechanisms Scientific Contributions The 15 most recent publications (2025-2023) demonstrate expertise in tumor immunology, tri-specific antibody engineering, and pan-cancer therapeutic strategies. Key trends include optimizing radioligand therapy for prostate cancer, characterizing immune cell infiltration in solid tumors, and addressing adverse events in T-cell and NK cell therapies.

Scott Stuart Maxwellمشاهده پروفایل

پژوهشگر ارشد

• Epigenetics
• Bioinformatics
• Diabetes
• +۷ مورد دیگر

Scott Stuart Maxwell is an Adjunct Research Fellow in Diabetes at Monash University, actively contributing to research in epigenetics, bioinformatics, and diabetic complications. His work spans molecular mechanisms of gene regulation, DNA methylation, and single-cell genomics in the context of diabetes and its associated diseases. Institution: Monash University Department: Diabetes Academic Rank: Research Fellow (Adjunct) Email: Scott.Maxwell1@monash.edu ORCID: https://orcid.org/0000-0002-7801-0714 Dr. Maxwell completed his PhD in Epigenetics/Bioinformatics, focusing on the biochemical characterisation of MeCP2 in the brain. His research has significantly contributed to understanding epigenetic regulation in diabetes, particularly in diabetic nephropathy, cardiovascular disease, and beta-cell dysfunction. His research interests include: Epigenetics and DNA Methylation Bioinformatics and RNA-Seq Diabetic Complications (nephropathy, retinopathy, cardiovascular) Gene Regulation and Chromatin Remodeling Single-Cell Genomics Molecular Mechanisms of Type 1 and Type 2 Diabetes The most recent articles (2021–2024) highlight a strong focus on epigenetic biomarkers, inflammatory pathways in diabetic kidney disease, beta-cell regeneration, and the role of methyltransferases in endothelial dysfunction. His work integrates molecular biology with clinical implications, aiming to identify novel therapeutic targets and early detection markers for diabetes complications. Scientific recognition includes extensive media coverage (picked up by over 60 news outlets), social media engagement (hundreds of X posts), and Mendeley readership, though no formal awards are listed. Dr. Maxwell serves as a Chief Investigator on active grants, such as the project on cytosine methylation in diabetic nephropathy progression (2021–2023), and is accepting PhD students, indicating an active mentoring role. His collaborative network includes leading researchers in diabetes and epigenetics at Monash and internationally. He is involved in a research lab or team focused on epigenetic mechanisms in metabolic disease, likely within the Diabetes department at Monash University, contributing to interdisciplinary studies on gene regulation in high-impact journals.

• Functional Genomics
• Systems Biology
• Pharmacogenomics
• +۱۱ مورد دیگر

Yuhui Hu is an Associate Professor and Doctoral Supervisor in the Department of Pharmacology, School of Medicine at Southern University of Science and Technology (SUSTech) in Shenzhen, China. She joined SUSTech in August 2016 as an independent PI and was promoted to Associate Professor in the Department of Pharmacology in March 2022, having previously served as a Research Associate Professor in the Department of Biology, School of Life Sciences at SUSTech from 2016-2022. Dr. Hu earned her Ph.D. in Functional Genomics from the Max Planck Institute for Molecular Genetics in Berlin, Germany in 2006. Prior to joining SUSTech, she led her own research group on pharmacogenomics and chemical genetics at the same institute from 2007-2009, then moved to the Berlin Institute for Medical Systems Biology (BIMSB) at the Max Delbrück Center for Molecular Medicine where she served as a Senior Research Scientist until 2016. Her research focuses on integrating diverse systems biology approaches in transcriptomics, genomics/epigenomics, proteomics, CRISPR gene editing, single-cell and spatiotemporal omics to decipher gene regulations in cancer precision medicine and developmental biology. She has pioneered high-throughput platforms for protein subcellular localization, apoptosis detection, and protein-protein interaction analysis. Her work bridges traditional Chinese medicine compounds with modern systems biology approaches to develop new drugs, particularly through the investigation of natural compounds for anticancer and anti-COVID applications. Her recent publications show a strong focus on cutting-edge single-cell and spatial transcriptomics technologies, with multiple high-impact papers in journals like Cell, Nature Communications, and Developmental Cell. Her research group has developed several innovative protocols for sample multiplexing and cell death quantification compatible with single-cell sequencing. Excellent Patent Award, Southern University of Science and Technology (2020) Industrial Development and Innovative Talent Award, Shenzhen (2021) Shenzhen Peacock Talent Award As a Doctoral Supervisor, Dr. Hu leads a research group that has secured significant funding, including six national/provincial projects totaling over ¥7.14 million. She serves as a core PI in the Shenzhen Key Laboratory of Gene Regulation and Systems Biology and holds several academic society positions, including committee member of the division of anti-inflammatory and immunological pharmacology of the Chinese Pharmacological Society, council member of Guangdong Pharmacological Society, and executive director of Guangdong Overseas Returnees Association. Her lab continues to develop novel systems biology approaches for gene regulation and pharmacology research, with a particular focus on cancer genomics and chemical genomics for early diagnosis, therapy, and prognosis.

Martin Engeمشاهده پروفایل

دانشیار

• Cancer Stem Cells
• Clonal Evolution
• Single-Cell Multiomics
• +۵ مورد دیگر

Martin Enge is a Senior Researcher and Associate Professor in the Department of Oncology-Pathology at Karolinska Institutet. He holds a Medicine Doctoral degree (2009) from Karolinska Institutet and has been recognized for developing innovative single-cell multiomics methodologies to study cancer biology. Employment: Senior Researcher (2022-), Associate Professor (2023) Location: Bioclinicum v6, Stockholm His research focuses on clonal evolution , gene regulation , and cell interaction in cancer, particularly in pediatric acute lymphoblastic leukemia (ALL) . He investigates how both genetic and epigenetic changes drive tumor progression and response to treatment, using advanced single-cell techniques to distinguish cancer stem cells from stochastic models of tumor growth. His 15 most recent publications span topics including MYC super-enhancer regulation , single-cell transcriptomics in psoriasis , pre-malignant subclones in neuroblastoma , and chromatin interactome in colorectal cancer . These works integrate genomic , transcriptomic , and computational approaches to decode complex disease mechanisms. Scientific Awards: Swedish Childhood Cancer Foundation grant (2021) He leads the research group Cancer stem cells and clonal structure in acute lymphoblastic leukemia at Karolinska Institutet, which has developed novel methods for analyzing functional and genetic errors in individual cells across leukemias and other cancers. His lab is actively involved in understanding pre-leukemic states , relapse mechanisms , and stromal interactions in tumor microenvironments.

• Chronic Kidney Disease
• Genetics
• Genomics
• +۵ مورد دیگر

Katalin Susztak is Professor of Medicine and Genetics at the Perelman School of Medicine, University of Pennsylvania. She holds hospital appointments at the Philadelphia VA Medical Center and leads kidney disease research through multiple institutional roles including codirector of the Institute of Diabetes and Obesity and Metabolism complications unit. MD and PhD from Semmelweis University, Hungary MS in Genomics and Computational Biology from Albert Einstein College of Medicine Her research focuses on molecular pathways in chronic kidney disease (CKD), integrating genetics, epigenetics, and single-cell transcriptomics to identify novel disease genes (e.g., MANBA, DACH1, APOL1) and demonstrate mechanisms like Notch signaling dysfunction and metabolic dysregulation. She pioneered kidney epigenome mapping and created the first cross-species single-cell kidney atlas. Recent publications highlight integrative multi-omics approaches, including 2025 work on proteogenomics and 2024 studies on ER stress/STING pathway roles in fibrosis. Her team also explores therapeutic implications of mineralocorticoid receptor antagonists and cytoskeletal regulators like WHAMM in kidney disease. 2011 Young Investigator Award (ASN/AHA) 2021 Alfred Newton Richards Award (ISN) Lab personnel include 15+ postdoctoral fellows, graduate students, and research specialists. She advises through the MD-PhD admissions committee and leads the Penn/CHOP Kidney Innovation Center. Funding sources include NIH, American Diabetes Association, and Juvenile Diabetes Research Foundation.

Ryan Listerمشاهده پروفایل

استاد

• Epigenetics
• Genomics
• DNA Methylation
• +۵ مورد دیگر

Professor Ryan Lister is a leading epigenetics and genomics researcher at the University of Western Australia (UWA) and head of the Epigenetics and Genomics laboratory at the Harry Perkins Institute of Medical Research. Elected as a Fellow of the Australian Academy of Science in 2020 and a joint Scientist of the Year in the Premier’s Science Awards, his work focuses on understanding the epigenome's role in gene regulation, cellular reprogramming, and disease. He holds the Sylvia and Charles Viertel Senior Medical Research Fellowship and has pioneered techniques like whole-genome bisulfite sequencing. BSc in Biochemistry and Genetics (UWA, 2000) PhD in Plant Mitochondrial Biogenesis (UWA, 2005) Postdoctoral Fellow (Salk Institute, 2006-2012) His research explores the epigenome's role in mammalian brain development, stem cell reprogramming, and plant biology. Techniques he developed, such as RNA-seq and ATAC-seq, enable high-resolution methylome mapping. Key findings include the first human DNA methylomes and epigenetic memory in iPSCs. Recent publications focus on synthetic gene circuits in plants, CRISPRi-based DNA methylation manipulation, and comparative methylome studies. His work spans both plant and human epigenetics, with implications for agriculture and medicine. Fellow of the Australian Academy of Science (2020) Joint Scientist of the Year (2020 Premier’s Science Awards) Sylvia and Charles Viertel Senior Medical Research Fellowship His lab collaborates on epigenome editing technologies and developmental biology. Current projects investigate DNA methylation readers, brain epigenomic diversity, and programmable gene expression systems.

• Cancer Genomics
• Tumor Heterogeneity
• Drug Resistance
• +۱۲ مورد دیگر

Mohammed Inayatullah Maula Ali is an Assistant Professor in the Department of Molecular Medicine at the Faculty of Health Sciences, University of Southern Denmark. His research focuses on tumor heterogeneity, drug resistance mechanisms in aggressive cancers, and the integration of single-cell multi-OMICS with computational and machine learning approaches for patient stratification. University: University of Southern Denmark School: Faculty of Health Sciences Department: Department of Molecular Medicine Position: Assistant Professor His research interests center on understanding the molecular and cellular basis of cancer progression, particularly in ovarian and triple-negative breast cancer. He leverages advanced technologies such as single-cell RNA sequencing, epigenomic profiling, and gene regulatory network analysis to identify cell populations driving aggressiveness and therapy resistance. His work also extends to neuroimmunology, including the role of regulatory T cells in remyelination. The recent publications highlight a strong trend in cancer genomics, epigenetic regulation, and immune signaling. Articles span topics from pan-cancer metastasis drivers to inflammasome activation via pathogen mimicry and T-cell aging in neurological repair. These studies employ high-throughput omics and computational modeling, emphasizing translational relevance in both oncology and regenerative medicine. Mohammed Inayatullah Maula Ali has no listed scientific awards in the provided text. There is no public information available regarding student advising or research grants. However, his extensive collaborative network, evident from co-authorship with international experts, suggests active engagement in large-scale research initiatives and potential supervision of trainees. His work is frequently highlighted in news outlets and academic platforms, indicating significant scientific impact. While specific laboratory or research team details are not mentioned, his research fingerprint includes expertise in single-cell genomics, epigenetics, and computational biology, suggesting leadership or active participation in a multidisciplinary research group focused on molecular oncology and systems biology.

H. Josh Jangمشاهده پروفایل

استادیار

• Epigenetics
• Immunotherapy
• Cancer Biology
• +۶ مورد دیگر

H. Josh Jang is an Assistant Professor in the Department of Cell Biology at Van Andel Institute , where he leads the Jang Laboratory focused on improving cancer immunotherapies through epigenetic and metabolic research. He joined the Institute in 2025 after serving as a VAI Fellow (2020-2025) under Nobel laureates Peter A. Jones and Stephen B. Baylin. Education : B.S. in Health Promotion and Disease Prevention (University of Southern California), Ph.D. in Molecular Genetics and Genomics (Washington University in St. Louis) Key Collaborations : Van Andel Institute–Stand Up To Cancer® Epigenetics Dream Team His research explores the epigenetic-metabolic crosstalk in cancer progression, targeting reversible vulnerabilities to enhance immune checkpoint inhibitors. Current projects include transposable element activation , RNA splicing dysregulation , and tumor microenvironment characterization using single-cell and spatial sequencing technologies. Recent publications demonstrate expertise in multi-omics analysis , clinical trial design , and epigenetic therapy optimization across diverse cancers. His work has generated 15 clinical trials through the VAI-SU2C Dream Team collaboration. Scientific Awards : K99/R00 Pathway to Independence grant (NCI) SPORE Epigenetic Therapies Career Enhancement Award (NCI) Forbeck Scholar (2021)

• 3-D genomics
• epigenomics
• chromatin topology
• +۵ مورد دیگر

Yuliang Feng is an Associate Professor and doctoral supervisor in the Department of Pharmacology, School of Medicine, Southern University of Science and Technology (SUSTech), China. He also serves as Vice-Chair of the Pan-Vascular Committee of the Guangdong Medical Education Association and holds editorial/reviewer roles for more than 25 international journals. Education Ph.D. in Molecular & Cellular Medicine, University of Oxford, UK (2019-2022) M.D. in Cardiovascular Pharmacology, Joint Ph.D. program, Southern Medical University & University of Cincinnati (2008-2014) B.M. in Preventive Medicine, Sun Yat-sen University, China (2003-2008) Research Interests Dr. Feng integrates 3-D genomics , epigenomics and computational biology to decode how higher-order chromatin organization governs transcriptional programs in human disease, with a focus on cardiovascular disease and cancer . His laboratory maps enhancer–promoter interactions using Hi-C, ChIA-PET and HiChIP, and develops multi-omics databases (e.g., EXPRESSO) to uncover therapeutic targets that reprogram pathological gene networks. Recent work reveals shared genetic architectures among major cardiovascular diseases, telomere-length contributions to disease onset, BRD9–SMAD2/3-mediated stemness in pancreatic cancer, and 3-D chromatin rewiring during dilated cardiomyopathy. These studies highlight his expertise in translating genome topology findings into diagnostic and precision-medicine strategies. Scientific Awards & Honors National Science Foundation of China Distinguished Young Scholar (Overseas), 2023 Guangdong Distinguished Young Scholar, 2023 Shenzhen Pengcheng Peacock Talent (Category C), 2023 Clarendon Scholar, University of Oxford, 2019-2022 ISHR Richard J. Bing Young Investigator Award Finalist, 2022 Multiple ISHR Young Investigator & Travel Awards (2010-2016) Grants & Leadership Dr. Feng currently leads projects funded by the National Natural Science Foundation of China and Guangdong Province, and participates in international consortia such as ENCODE, 4DN and BLUEPRINT. He mentors graduate students and postdocs, while coordinating collaborative teams across SUSTech, Oxford, and industry partners to develop next-generation epigenomic therapeutics. Laboratory & Teams The Feng lab operates within the SUSTech Medical Research Platform with access to state-of-the-art sequencing, single-cell and high-performance computing cores. The group maintains active collaborations with cardiac surgeons, oncologists and AI scientists to accelerate bench-to-bedside translation of 3-D genome-based interventions.